TY - JOUR
T1 - Uniting biobank resources reveals novel genetic pathways modulating susceptibility for atopic dermatitis
AU - Sliz, Eeva
AU - Huilaja, Laura
AU - Pasanen, Anu
AU - Laisk, Triin
AU - Reimann, Ene
AU - Mägi, Reedik
AU - Hannula-Jouppi, Katariina
AU - Peltonen, Sirkku
AU - Salmi, Teea
AU - Koulu, Leena
AU - Tasanen, Kaisa
AU - Kettunen, Johannes
N1 - Funding Information:
The FinnGen project is funded by 2 grants from Business Finland (grant nos. HUS 4685/31/2016 and UH 4386/31/2016) and the following industry partners: AbbVie Inc, AstraZeneca UK Ltd, Biogen MA Inc, Celgene Corporation, Celgene International II Sàrl, Genentech Inc, Merck Sharp & Dohme Corp, Pfizer Inc, GlaxoSmithKline Intellectual Property Development Ltd, Sanofi US Services Inc, Maze Therapeutics Inc, Janssen Biotech Inc, and Novartis AG. This study was funded by the Sigrid Juselius Foundation (J.K.), the Academy of Finland (grant nos. 297338 and 307247 to J.K.), Novo Nordisk Foundation (grant no. NNF17OC0026062 to J.K.), the European Union through the European Regional Development Fund (project nos. 2014-2020.4.01.15-0012 and 2014-2020.4.01.16-0125), the European Union (through Horizon 2020 grant no. 810645), and the Estonian Research Council grants (grant nos. PRG687 and PRG1291).
Publisher Copyright:
© 2021 The Authors
PY - 2022
Y1 - 2022
N2 - Background: Atopic dermatitis (AD) is a common chronic inflammatory skin disease with high heritability. Previous genome-wide association studies have identified several loci predisposing to AD. These findings explain approximately 30% of the variance in AD susceptibility, suggesting that further work is required to fully understand the genetic underpinnings. Objective: We sought to gain additional understanding of the genetic contribution to AD risk by using biobank resources. Methods: We completed a genome-wide meta-analysis of AD in 796,661 individuals (Ncases = 22,474) from the FinnGen study, the Estonian Biobank, and the UK Biobank. We further performed downstream in silico analyses to characterize the risk variants at the novel loci. Results: We report 30 loci associating with AD (P < 5 × 10−8), 5 of which are novel. In 2 of the novel loci, we identified missense mutations with deleterious predictions in desmocollin 1 and serpin family B member 7, genes encoding proteins crucial to epidermal strength and integrity. Conclusions: These findings elucidate novel genetic pathways involved in AD pathophysiology. The likely involvement of desmocollin 1 and serpin family B member 7 in AD pathogenesis may offer opportunities for the development of novel treatment strategies for AD in the future.
AB - Background: Atopic dermatitis (AD) is a common chronic inflammatory skin disease with high heritability. Previous genome-wide association studies have identified several loci predisposing to AD. These findings explain approximately 30% of the variance in AD susceptibility, suggesting that further work is required to fully understand the genetic underpinnings. Objective: We sought to gain additional understanding of the genetic contribution to AD risk by using biobank resources. Methods: We completed a genome-wide meta-analysis of AD in 796,661 individuals (Ncases = 22,474) from the FinnGen study, the Estonian Biobank, and the UK Biobank. We further performed downstream in silico analyses to characterize the risk variants at the novel loci. Results: We report 30 loci associating with AD (P < 5 × 10−8), 5 of which are novel. In 2 of the novel loci, we identified missense mutations with deleterious predictions in desmocollin 1 and serpin family B member 7, genes encoding proteins crucial to epidermal strength and integrity. Conclusions: These findings elucidate novel genetic pathways involved in AD pathophysiology. The likely involvement of desmocollin 1 and serpin family B member 7 in AD pathogenesis may offer opportunities for the development of novel treatment strategies for AD in the future.
KW - Atopic dermatitis
KW - DSC1
KW - FinnGen
KW - genome-wide association
KW - SERPINB7
U2 - 10.1016/j.jaci.2021.07.043
DO - 10.1016/j.jaci.2021.07.043
M3 - Article
C2 - 34454985
AN - SCOPUS:85115934486
SN - 0091-6749
JO - Journal of Allergy and Clinical Immunology
JF - Journal of Allergy and Clinical Immunology
ER -